...
首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop.
【24h】

Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop.

机译:药物性肝损伤的命名法和因果关系评估的标准化:临床研究研讨会的摘要。

获取原文
获取原文并翻译 | 示例

摘要

Idiosyncratic drug-induced liver injury (DILI) is an important but relatively infrequent cause of potentially severe acute and chronic liver injury. The aim of this clinical research workshop was to review and attempt to standardize the current nomenclature and terminology used in DILI research. Because DILI is a diagnosis of exclusion, selected elements of the medical history, laboratory tests, and previous reports were proposed to improve causality assessment. Definitions and diagnostic criteria regarding the onset of DILI, evolution of liver injury, risk factors, and mandatory testing versus optional testing for competing causes were reviewed. In addition, the role of intentional and inadvertent rechallenge, liver histology, and host genetic polymorphisms in establishing the diagnosis and prognosis of DILI were reviewed. Consensus was established regarding the need to develop a web-of-knowledge database that provides concise, reliable, and updated information on cases of liver injury due to drugs and herbal and dietary supplements. In addition, the need to develop drug-specific computerized causality assessment methods that are derived from prospectively phenotyped cases was a high priority. Proposed scales for grading DILI severity and assessing the likelihood of an agent causing DILI and written criteria for improving the reliability, accuracy, and reproducibility of expert opinion were reviewed. Finally, the unique challenges of assessing causality in children, patients with underlying liver disease, and subjects taking herbal and dietary supplements were discussed. Conclusion: Workshop participants concluded that multicenter referral networks enrolling patients with suspected DILI according to standardized methodologies are needed. These networks should also collect biological samples that may provide crucial insights into the mechanism(s) of DILI with the ultimate aim of preventing future cases of DILI.
机译:特异药物性肝损伤(DILI)是潜在的严重急性和慢性肝损伤的重要但相对罕见的原因。该临床研究研讨会的目的是回顾和尝试标准化DILI研究中使用的当前术语和术语。由于DILI是排除诊断,因此提出了病史,实验室检查和以前的报告中的某些要点,以改善因果关系评估。回顾了有关DILI发作,肝损伤的演变,危险因素,强制性检测与竞争性原因的选择性检测的定义和诊断标准。此外,还综述了有意和无意的再挑战,肝脏组织学以及宿主遗传多态性在建立DILI诊断和预后中的作用。建立了关于需要开发知识网络数据库的共识,该数据库可提供有关药物,草药和膳食补充剂引起的肝损伤病例的简明,可靠和最新的信息。此外,迫切需要开发从前瞻性表型病例衍生的针对药物的计算机化因果关系评估方法。审查了拟定DILI严重性等级和评估导致DILI的药物的可能性的量表以及提高专家意见的可靠性,准确性和可再现性的书面标准。最后,讨论了评估儿童,潜在肝病患者以及服用草药和膳食补充剂的因果关系的独特挑战。结论:研讨会的参与者得出结论,需要采用标准化方法将怀疑可疑DILI的患者纳入多中心转诊网络。这些网络还应收集可能为DILI机制提供重要见解的生物学样本,其最终目的是防止DILI的未来病例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号